To the best of our knowledge, we demonstrated for the first time that regorafenib and its active metabolites, M2 and M5, inhibit MICA shedding in human CRC cell lines (Fig. 2A) without cytotoxic effects. Here, MICA is linked to colorectal carcinoma.